Search tips
Search criteria 


Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
Antimicrob Agents Chemother. 1991 November; 35(11): 2246–2252.
PMCID: PMC245367

Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity.


A prospective, randomized, and double-blind study comparing teicoplanin with vancomycin in the initial management of febrile neutropenic patients was conducted. Teicoplanin was administered at 6 mg per kg of body weight every 24 h (q24h) intravenously (i.v.) after initial loading at 6 mg/kg q12h for three doses. Vancomycin was administered at 15 mg/kg q12h i.v. Patients also received piperacillin (3 g q4h i.v.) and tobramycin (1.5 to 2.0 mg/kg q8h i.v.). Of 53 patients enrolled, 50 were judged to be evaluable. Among these, 25 received teicoplanin and 25 received vancomycin. At enrollment, both groups were comparable in age, sex, renal function, underlying hematologic condition, and concurrent therapy. Both groups had similar sites of infection and microbial pathogens. Empirical antimicrobial therapy resulted in the cure of or improvement in 23 (92%) teicoplanin patients and 21 (84%) vancomycin patients (P = 0.67). Failures occurred with two vancomycin patients but no teicoplanin patients. Clinical response was indeterminate for two patients in each group. Adverse reactions occurred significantly more often in the vancomycin group than in the teicoplanin group (P = 0.01), and these reactions required the termination of the study regimens of 6 vancomycin versus 0 teicoplanin patients (P = 0.02). Nephrotoxicity was observed more frequently in the vancomycin group (10 versus 2 patients; P = 0.02). Subgroup analysis revealed a significant deterioration of renal function when vancomycin and cyclosporin A, but not teicoplanin and cyclosporin A, were used concurrently (P = 0.02). Among patients who received vancomycin and amphotericin B or teicoplanin and amphotericin B concurrently, deterioration in renal function was equivalent in both groups. Teicoplanin in the dosage employed was tolerated better than vancomycin in the empirical treatment of fever and neutropenia in our patient population.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.4M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Aubert G, Passot S, Lucht F, Dorche G. Selection of vancomycin- and teicoplanin-resistant Staphylococcus haemolyticus during teicoplanin treatment of S. epidermidis infection. J Antimicrob Chemother. 1990 Mar;25(3):491–493. [PubMed]
  • Babul N, Pasko M. Teicoplanin: a new glycopeptide antibiotic complex. Drug Intell Clin Pharm. 1988 Mar;22(3):218–226. [PubMed]
  • Brunet F, Vedel G, Dreyfus F, Vaxelaire JF, Giraud T, Schremmer B, Monsallier JF. Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin. Eur J Clin Microbiol Infect Dis. 1990 Feb;9(2):145–147. [PubMed]
  • Calain P, Krause KH, Vaudaux P, Auckenthaler R, Lew D, Waldvogel F, Hirschel B. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis. 1987 Feb;155(2):187–191. [PubMed]
  • Calain P, Waldvogel F. Clinical efficacy of teicoplanin. Eur J Clin Microbiol Infect Dis. 1990 Feb;9(2):127–129. [PubMed]
  • Chambers HF, Kennedy S. Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob Agents Chemother. 1990 Apr;34(4):510–514. [PMC free article] [PubMed]
  • Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. [PubMed]
  • Farber BF, Moellering RC., Jr Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother. 1983 Jan;23(1):138–141. [PMC free article] [PubMed]
  • Goldstein FW, Coutrot A, Sieffer A, Acar JF. Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci. Antimicrob Agents Chemother. 1990 May;34(5):899–900. [PMC free article] [PubMed]
  • Greenberg RN, Benes CA. Time-kill studies with oxacillin, vancomycin, and teicoplanin versus Staphylococcus aureus. J Infect Dis. 1990 May;161(5):1036–1037. [PubMed]
  • Hackbarth CJ, Chambers HF. Methicillin-resistant staphylococci: genetics and mechanisms of resistance. Antimicrob Agents Chemother. 1989 Jul;33(7):991–994. [PMC free article] [PubMed]
  • Johnson AP, Uttley AH, Woodford N, George RC. Resistance to vancomycin and teicoplanin: an emerging clinical problem. Clin Microbiol Rev. 1990 Jul;3(3):280–291. [PMC free article] [PubMed]
  • Kaatz GW, Seo SM, Dorman NJ, Lerner SA. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J Infect Dis. 1990 Jul;162(1):103–108. [PubMed]
  • Karp JE, Dick JD, Angelopulos C, Charache P, Green L, Burke PJ, Saral R. Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med. 1986 Aug;81(2):237–242. [PubMed]
  • Kureishi A, Jewesson PJ, Bartlett KH, Cole CD, Chow AW. Application of a modified bioassay for monitoring serum teicoplanin and vancomycin in febrile neutropenic patients. Antimicrob Agents Chemother. 1990 Sep;34(9):1642–1647. [PMC free article] [PubMed]
  • Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med. 1988 Jul 21;319(3):157–161. [PubMed]
  • Leport C, Perronne C, Massip P, Canton P, Leclercq P, Bernard E, Lutun P, Garaud JJ, Vilde JL. Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients. Antimicrob Agents Chemother. 1989 Jun;33(6):871–876. [PMC free article] [PubMed]
  • Lewis P, Garaud JJ, Parenti F. A multicentre open clinical trial of teicoplanin in infections caused by gram-positive bacteria. J Antimicrob Chemother. 1988 Jan;21 (Suppl A):61–67. [PubMed]
  • Martino P, Venditti M, Micozzi A, Brandimarte C, Gentile G, Santini C, Serra P. Teicoplanin in the treatment of gram-positive-bacterial endocarditis. Antimicrob Agents Chemother. 1989 Aug;33(8):1329–1334. [PMC free article] [PubMed]
  • Maugein J, Pellegrin JL, Brossard G, Fourche J, Leng B, Reiffers J. In vitro activities of vancomycin and teicoplanin against coagulase-negative staphylococci isolated from neutropenic patients. Antimicrob Agents Chemother. 1990 May;34(5):901–903. [PMC free article] [PubMed]
  • Menichetti F, Del Favero A, Bucaneve G, Aversa F, Baldelli F, Felicini R, Terenzi A, Pauluzzi S. Teicoplanin in empirical combined antibiotic therapy of bacteraemias in bone marrow transplant patients. J Antimicrob Chemother. 1988 Jan;21 (Suppl A):105–111. [PubMed]
  • Nicas TI, Wu CY, Hobbs JN, Jr, Preston DA, Allen NE. Characterization of vancomycin resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother. 1989 Jul;33(7):1121–1124. [PMC free article] [PubMed]
  • Nováková IR, Donnelly JP, Verhagen CS, De Pauw BE. Teicoplanin as modification of initial empirical therapy in febrile granulocytopenic patients. J Antimicrob Chemother. 1990 Jun;25(6):985–993. [PubMed]
  • Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med. 1988 Jan;108(1):30–35. [PubMed]
  • Sahai J, Healy DP, Shelton MJ, Miller JS, Ruberg SJ, Polk R. Comparison of vancomycin- and teicoplanin-induced histamine release and "red man syndrome". Antimicrob Agents Chemother. 1990 May;34(5):765–769. [PMC free article] [PubMed]
  • Shenep JL, Hughes WT, Roberson PK, Blankenship KR, Baker DK, Jr, Meyer WH, Gigliotti F, Sixbey JW, Santana VM, Feldman S, et al. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med. 1988 Oct 20;319(16):1053–1058. [PubMed]
  • Smith SR, Cheesbrough J, Harding I, Davies JM. Role of glycopeptide antibiotics in the treatment of febrile neutropenic patients. Br J Haematol. 1990 Dec;76 (Suppl 2):54–56. [PubMed]
  • Smith SR, Cheesbrough J, Spearing R, Davies JM. Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters. Antimicrob Agents Chemother. 1989 Aug;33(8):1193–1197. [PMC free article] [PubMed]
  • Wade JC. Antibiotic therapy for the febrile granulocytopenic cancer patient: combination therapy vs. monotherapy. Rev Infect Dis. 1989 Nov-Dec;11 (Suppl 7):S1572–S1581. [PubMed]
  • Weems JJ, Jr, Lowrance JH, Baddour LM, Simpson WA. Molecular epidemiology of nosocomial, multiply aminoglycoside resistant Enterococcus faecalis. J Antimicrob Chemother. 1989 Aug;24(2):121–130. [PubMed]
  • Yao JD, Thauvin-Eliopoulos C, Eliopoulos GM, Moellering RC., Jr Efficacy of teicoplanin in two dosage regimens for experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother. 1990 May;34(5):827–830. [PMC free article] [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)